Find Academic Supervisors

William B. TabayoyongView profile

Assistant Professor

• Urologic Oncology
• Immunotherapy
• Bladder Cancer
• +4 more

William B. Tabayoyong, M.D., Ph.D., is an Assistant Professor in the Department of Urology at the University of Rochester School of Medicine and Dentistry. He specializes in Urologic Oncology, with expertise in minimally invasive robotic surgery for bladder, prostate, and kidney cancers, as well as advanced open pelvic and retroperitoneal cancer surgery. Educated at the University of Iowa (MD/PhD in Immunology, 2011) Urology residency at Case Western Reserve University (2012–2017) Society of Urologic Oncology fellowship at MD Anderson Cancer Center (2017–2019) His research focuses on immunotherapy for urologic cancers, particularly bladder cancer. He has led clinical trials on intravesical TARA-002 for high-grade non-muscle invasive bladder cancer and published extensively on treatment protocols, surgical approaches, and biomarkers in urothelial cancers. His work emphasizes optimizing chemotherapy timing, multidisciplinary care, and advanced imaging techniques for prostate cancer diagnosis. Dr. Tabayoyong is board-certified in Urology and actively participates in the University of Rochester Medical Faculty Group (URMFG) and Accountable Health Partners (AHP). He has received consistently high patient satisfaction scores for compassionate care, thorough explanations, and shared decision-making.

• Urology
• Cardiothoracic Surgery
• Oncological Surgery
• +4 more

Magnus Larsen serves as an Associate Professor in the Department of Clinical Medicine at UiT The Arctic University of Norway in Tromsø, maintaining active dual research trajectories in urological oncology and cardiothoracic surgery. His primary research domains include: Urological surgical innovations for bladder and prostate cancer Acute aortic dissection management and surgical techniques Comparative effectiveness of minimally invasive versus open surgical approaches Oncological outcomes in genitourinary malignancies Recent publication analysis (2023-2025) reveals intensified focus on urological oncology, particularly robotic prostatectomy outcomes and cystectomy techniques, while his foundational work (2013-2017) established significant contributions to the International Registry of Acute Aortic Dissections (IRAD). This dual expertise manifests in high-impact studies spanning surgical morbidity reduction, neoadjuvant therapy efficacy, and aortic dissection pathophysiology. Laboratory and team affiliations are anchored in UiT's Urology research group, where he collaborates on translational surgical projects bridging clinical practice and academic research.

• Cancer and Oncology
• Immunology in the medical area
• Respiratory Medicine and Allergy
• +3 more

Susanne Gabrielsson is a Professor of Immunology at Karolinska Institutet's Department of Medicine, Solna. She leads the 'Extracellular Vesicles in Immunity' research group, focusing on exosomes' roles in immunity, cancer, and lung diseases. She holds academic positions including former Associate Professor (2008–2018) and has served on KI's Junior Faculty, Board of Research, and Council for Environment and Sustainable Development. Education: BSc in Molecular Biology, Linköping University (1994) PhD in Molecular Biology, Stockholm University (1999) Postdoctoral Research at Institut Curie, Paris (1999–2001) Research Interests: Extracellular vesicles (EVs) are central to her work, exploring their roles in physiological processes like immune regulation, cancer progression, and lung diseases such as sarcoidosis and COPD. Her lab investigates EV mechanisms for developing therapies using EVs in cancer immunotherapy and diagnostics. Articles Trends: Recent work highlights EVs in cancer immunotherapy (e.g., antigen-loaded EVs enhancing T cell responses), diabetes complications (EV-mediated endothelial dysfunction), and asthma pathogenesis (EV signaling in T cell reprogramming). Over 130 publications span EV biology, clinical applications, and diagnostic tools. Scientific Awards & Grants: Swedish Research Council grants Swedish Cancer Society and Heart-Lung Foundation funding Cancer and Allergy Fund awards (2024, 2022, 2021, 2019) Advising & Grants: Funded projects include EV-based cancer vaccines and diabetes mechanisms. Her work bridges basic EV biology with translational medicine. Labs & Teams: Her research group collaborates widely, focusing on EV cargo analysis, immune modulation, and disease biomarkers. Key partnerships include the KI Board of Research and international EV consortia.

Aniko SzaboView profile

Professor

• Biostatistics
• Statistical Modeling of Biomedical Data
• Cancer Screening Analysis
• +4 more

Aniko Szabo, PhD, is a Professor and Director of the Biostatistics Consulting Center at the Medical College of Wisconsin. Her research focuses on statistical modeling of biomedical data, including cancer screening analysis, oncogenesis, and translational research across cellular assays, animal studies, observational trials, and clinical policy evaluation. She holds a PhD in Applied Statistics from the University of Memphis (1998) and an MS in Mathematics from Eötvös University, Budapest (1994). Dr. Szabo’s work spans diverse biomedical areas: analyzing PCR/microarray data, developing oncogenesis tree models, nonparametric clustering methods, and population-level screening impact models. She collaborates across disciplines, contributing to studies on trauma pain management, radiation-induced cardiac damage, multiple myeloma immunotherapies, sleep deprivation effects on opioid withdrawal, and bariatric surgery outcomes. Her 2025 publications include studies on teclistamab/talquetamab treatment patterns (Blood Cancer J), ketamine efficacy in trauma patients (J Trauma Acute Care Surg), and CAR-T cell innovations for mantle cell lymphoma (J Clin Oncol). Her leadership includes directing the Biostatistics Consulting Service, supporting translational research from bench to clinical practice. Notable recent work addresses social determinants of health in oncology and quality improvement initiatives for sleep apnea monitoring. These efforts bridge statistical rigor with clinical relevance, impacting both patient care and policy decisions.

Thomas BoyerView profile

Professor

• Uterine Fibroids
• Gene Mutations (MED12)
• Wnt/β-Catenin Signaling
• +3 more

Dr. Thomas Boyer is a Professor in the Department of Molecular Medicine at UT Health San Antonio, specializing in the molecular mechanisms of uterine fibroids and related oncogenic pathways. His research focuses on MED12 mutations, Wnt/β-catenin signaling, and epigenetic reprogramming in uterine tumors. NIH R01 Grant ($1.56 million) NIH R01 Multi-PI Grant ($3.8 million) Dr. Boyer's work explores the interplay between vitamin D deficiency and genomic instability in MED12-mutant uterine fibroids, aiming to develop non-surgical therapies. He collaborates with Dr. Robert Schenken (UT Health San Antonio) and Dr. Ayman Al-Hendy (University of Illinois at Chicago). His recent publications highlight: Mediator kinase module as a therapeutic target in oncogenic Wnt signaling Role of BET proteins in inflammation and fibroid progression Epigenetic reprogramming via N6-methyladenosine in fibroid pathogenesis Myeloid-derived suppressor cells in cancer immunosuppression

Hamid GhaediView profile

Research Fellow

• Cell biology
• Genetics
• Genome structure and stability
• +5 more

Dr. Hamid Ghaedi is a Postdoctoral Fellow at Queen's University, affiliated with the Department of Pathology and Molecular Medicine within the School of Medicine, Faculty of Health Sciences. He specializes in Genomic Data Science, with a focus on analyzing genetic data from Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and RNA sequencing in oncology samples. His research interests include cell biology, genetics, genome structure stability, and genomics. Dr. Ghaedi holds a Ph.D. in Medical Genetics (2016, Shahid Beheshti University), an M.Sc. in Medical Biotechnology (2012, Tehran University), and a B.Sc. in Clinical Laboratory Science (2008, Shiraz University). He is actively involved in drug discovery, particularly using generative AI for de novo protein design and novel drug development. His work bridges genomic analysis with translational applications in precision medicine. His research trends emphasize genomic variability in oncology, immune-oncology biomarkers, and lncRNA/miRNA roles in disease. Recent studies include genetic mutation analysis in cancers, biomarker identification in bladder and breast cancers, and genotype-phenotype correlations in hereditary disorders. He collaborates with the Berman Lab and utilizes advanced bioinformatics tools for variant prioritization and predictive modeling. Dr. Ghaedi is committed to advancing genomic data science applications in clinical diagnostics and therapeutic innovation, leveraging both experimental and computational approaches.

Dickon HayneView profile

Professor

• Urological Cancer
• Bladder Cancer
• Prostate Cancer
• +3 more

Professor Dickon Hayne is a clinical academic at The University of Western Australia (UWA), leading urological research and education in urology. He holds positions as a consultant urological surgeon and Head of Urology for the South Metropolitan Health Service, WA. His research focuses on urological cancers, particularly bladder and prostate cancer, with emphasis on outcomes research, epidemiology, and minimally invasive surgery. He chairs the Bladder, Urothelial and Penile (BUP) Cancer Sub-committee of ANZUP and leads trials such as BCGMM and SUBDUE. Education: MBBS, St Mary’s Hospital, London (1994) MD (Research Fellow, University College London, 2003) FRCS (Eng) 1998, FRCS Urol 2006, FRACS 2011 Research Interests: Bladder cancer treatment, including BCG and mitomycin therapies, sub-urothelial immunotherapy (SUBDUE trials), and clinical trial innovations. Prostate cancer management, exercise interventions, and telehealth approaches. Development of patient-reported symptom indices and AI-driven biomarkers. Grants & Awards: Recipient of 2023 Certificate of Excellence in Teaching and British Journal of Urology International Global Prize Lead investigator for major grants including NHMRC-funded BCG+MM Trial ($1.5M), SUBDUE series, and WA Cancer Network grants Active in ANZUP trials and global urological oncology collaborations Labs & Teams: Leads ANZUP BUP subcommittee, collaborates with Valar Labs on AI biomarkers, and directs cystectomy databases and clinical trials.

Ronald De WitView profile

Professor

• Genitourinary Oncology
• Systemic Cancer Treatment
• Prostate Cancer Research
• +3 more

Professor Ronald De Wit is a Full Professor and Medical Oncologist at the Erasmus MC Cancer Institute, Erasmus University Rotterdam. He specializes in Genitourinary Oncology, focusing on systemic treatments for urothelial, prostate, renal cell, and germ cell cancers. Since 1990, he has led international clinical trials, including pivotal studies in taxane-based chemotherapies and immunotherapies like pembrolizumab. He chairs the Dutch Uro-Oncology Study Group and has held leadership roles in EORTC, ESMO, and ASCO committees. His research integrates translational pathology and urology collaborations, emphasizing biomarker discovery and patient outcomes. He has over 350 publications and received visiting professorships at MSKCC, American University Beirut, and King Hussein Cancer Center. Education: Medical degree from University of Amsterdam. Career: Erasmus MC since 1990. Research: Key contributions include the CARD trial for cabazitaxel efficacy and the IGCCCG update for germ cell cancer classification. Awards: Multiple visiting professorships and industry advisory roles. Advising/Grants: Principal investigator in phase III trials, Industry Advisory Board memberships, and Data Monitoring Committees. Labs/Teams: Collaborates with Urology and Translational Pathology departments, leading the Dutch Uro-Oncology Study Group (27 hospitals).

Simon BakerView profile

Research Fellow

• Genomics
• Cancer Research
• Molecular Biology
• +3 more

Dr. Simon Baker is a Kidney Research UK Intermediate Fellow at the Jack Birch Unit for Molecular Carcinogenesis within the Department of Biology at the University of York. His research focuses on genomic and transcriptomic methods to study DNA damage and mutational signatures in bladder cancer. He investigates how BK polyomavirus induces APOBEC-mediated genomic damage, linking viral infections to cancer etiology. His work combines experimental models, clinical data, and public involvement to improve bladder cancer diagnosis and treatment strategies. Research Interests: Dr. Baker’s primary focus is on understanding the molecular mechanisms underlying bladder cancer initiation, particularly the role of mutational signatures and viral infections. His studies explore APOBEC enzymes’ contributions to genomic instability, viral oncogenesis pathways, and the interplay between environmental toxins and genetic mutations. He also develops in vitro models to simulate carcinogenesis processes and validate therapeutic targets. Scientific Contributions: His publications emphasize mutational signature analysis, BKPyV pathogenesis, and clinical surveillance strategies for bladder cancer. The most recent articles highlight advancements in linking viral infections to cancer through APOBEC activation and refining patient care protocols. Awards and Recognition: He holds the prestigious Kidney Research UK Intermediate Fellowship, supporting his exploration of BKPyV as a bladder cancer driver. His research integrates clinical relevance with basic science, aiming to translate findings into improved patient outcomes. Teaching and Outreach: Dr. Baker leads educational initiatives through York Against Cancer’s Enthuse partnership, enhancing cancer education in secondary schools. He supervises students across undergraduate, master’s, and doctoral programs, fostering the next generation of biomedical researchers.

Andreas CarusView profile

Associate Clinical Professor

• Treatment of Urothelial Cancer
• Immune System in Cancer
• Cancer-Related Malnutrition/Sarcopenia
• +3 more

Andreas Carus is a Clinical Associate Professor and Overlæge at Aalborg University Hospital , affiliated with the Department of Oncology within the Faculty of Medicine . His primary research focuses on urothelial cancer treatment, immune system interactions with cancer, and cancer-related malnutrition (sarcopenia). He chairs the Danish Medical Council group on bladder cancer and serves on the board of the Danish Bladder Cancer Group (DaBlaCa). He holds a PhD (2013) in Chronic inflammation and cancer: Prognostic impact of neutrophils and macrophages in solid tumor . His work emphasizes real-world studies evaluating novel therapies and patient-reported outcomes, collaborating with institutions like the Clinical Research Unit (CRU) and Clinical Cancer Research Center (CCRC). Key research contributions include the DaBlaCa-17 observational study on bladder cancer survival and the TOMBOLA trial exploring ctDNA-based immunotherapy strategies. He has supervised 2 PhD students and actively participates in review committees and advisory roles.

• Urology
• Bladder Cancer
• Muscle-Invasive Bladder Cancer
• +7 more

Joost Boormans is a Full Professor in the Department of Urology at Erasmus MC, a leading academic medical center in the Netherlands. His clinical and research expertise lies in urological oncology, with a strong focus on bladder cancer and surgical oncology. His research interests center on improving outcomes in bladder cancer through translational and clinical studies. Key areas include the management of non-muscle-invasive and muscle-invasive bladder cancer, the role of neoadjuvant chemotherapy, oncological outcomes after cystectomy, and the development of molecular biomarkers to guide personalized treatment decisions. He actively contributes to nationwide and multicenter studies, leveraging real-world data and advanced molecular modeling. The recent publication trends indicate a strong emphasis on precision oncology, patient cohort analyses, and integrative models using tumoroids and genomic data. His work spans clinical trials, systematic reviews, and translational research, reflecting a multidisciplinary approach to urothelial cancer. Dr. Boormans has supervised multiple doctoral and research-level students, as indicated by the 'Supervised Work' section, although specific names are not listed. He collaborates extensively across institutions and countries, particularly in large-scale clinical studies. While no specific grants are mentioned, his involvement in nationwide and multicountry research suggests active funding support. He is part of research teams focusing on genitourinary oncology, molecular diagnostics, and surgical outcomes, contributing to both clinical practice and scientific advancement in urology.

• Prostate Cancer
• Bladder Cancer
• Radiation Therapy
• +3 more

Mette Moe serves as a Senior Physician (Overlæge) at Aalborg University Hospital within the Faculty of Medicine's Department of Oncology. Her research focuses on genitourinary cancers with particular expertise in prostate and bladder cancer treatment modalities. Her primary research interests include: Prostate cancer therapeutics and outcomes Patient-reported outcome measures in oncology Radiation therapy safety and efficacy Chemotherapy regimens for urothelial cancers Molecular imaging applications in cancer management Analysis of her recent publications reveals a strong focus on precision oncology approaches, particularly PSMA-targeted radioligand therapy for prostate cancer as demonstrated in the VISION trial publications. Her work consistently integrates both physician-assessed and patient-reported outcomes, reflecting a patient-centered research approach. The publications span clinical trials methodology, safety analyses, and comparative treatment efficacy studies with emphasis on real-world applications. Moe actively collaborates with multidisciplinary research teams across Denmark and internationally, as evidenced by her co-authorship on major clinical trials. Her work has generated significant academic attention with multiple publications garnering substantial citations and media coverage, including an upcoming media event in August 2025 regarding real-world data on PSMA PET/CT imaging prior to salvage radiotherapy. She contributes to both clinical practice and research within the Department of Oncology, with particular involvement in studies examining treatment-related morbidity and quality of life outcomes for cancer patients undergoing radiation and systemic therapies.

• Urothelial Cancer Genomics
• Bladder Cancer Subtypes
• Molecular Classification
• +5 more

Pontus Eriksson is an Associate Researcher at Lund University Cancer Centre (LUCC), focusing on urothelial cancer genomics and molecular classification. His work integrates bioinformatics, transcriptomics, and clinical data to improve bladder cancer diagnosis and treatment strategies. Key projects include the development of the LundTax classification algorithm and collaborations on metastasis patterns and immune microenvironment analysis. He has contributed to over 49 peer-reviewed publications and supervised research activities in bladder cancer biology. Research Interests: Molecular subtyping of bladder cancer, genomic profiling, immune response characterization, and translational oncology. His work aligns with UN Sustainable Development Goals related to health and well-being. Projects: Gene expression-based classification of urothelial carcinoma for clinical applications (2022–2023). Activities: Organized conferences such as the 7th Swedish Cancer Research Meeting (2025) and participated in initiatives like the UroCAN clinical translation project. Publications highlight advancements in bladder cancer subtyping, metastasis dynamics, and biomarker discovery. Collaborations span international cohorts to validate molecular classification systems.

David J VanderWeeleView profile

Associate Professor

• Oncology
• Clinical Trials
• Prostate Cancer Treatment
• +7 more

David J VanderWeele is an Associate Professor in the Department of Medicine at Northwestern University's Feinberg School of Medicine, specializing in Hematology and Oncology. His work focuses on precision medicine, clinical trials in metastatic cancer, and genomic profiling of prostate, bladder, and urothelial cancers. He leads several active clinical trials evaluating novel therapies, including immunotherapy combinations, targeted drug regimens, and molecularly guided treatments. Research Interests: His research emphasizes molecular mechanisms of treatment resistance in prostate cancer, the role of genomic heterogeneity in therapeutic outcomes, and the application of advanced imaging (e.g., PSMA-PET, FDG-PET) for guiding personalized treatment strategies. He also explores the integration of immunotherapies like checkpoint inhibitors and antibody-drug conjugates into standard oncology protocols. Clinical Trials: Key trials include evaluating nivolumab/relatlimab in bladder cancer, FOR46 (CD46-targeted ADC) in mCRPC, and the Metacure trial for oligometastatic prostate cancer. He has also contributed to trials examining PARP inhibitors in combination therapies and the impact of neoadjuvant androgen deprivation therapy on tumor response. Focus Areas: Prostate cancer progression, metastasis biology, biomarker-driven therapy selection, and overcoming resistance through multi-agent regimens. His work spans translational research (e.g., circulating tumor cells) and clinical implementation of precision medicine strategies.

• Cancer Stem Cells
• MAPK Signaling
• Bladder Cancer Research
• +2 more

Dr. Neha Sahay is a researcher affiliated with Newcastle University, focusing on cancer biology and molecular signaling pathways in bladder cancer. Her work explores mechanisms of tumor maintenance and stem cell dynamics. In 2012, she co-authored a pivotal study on the role of MAPK signaling in sustaining cancer stem cells within non-muscle invasive bladder cancer. This research contributes to understanding tumor heterogeneity and potential therapeutic targets. While her full academic profile and affiliations remain unspecified in the available text, her publications highlight expertise in oncology and molecular biology. No awards, students, or additional details are documented in the provided content.